ETON Eton Pharmaceuticals Inc.

6.99
+0.09  (+1%)
Previous Close 6.9
Open 6.95
Price To Book 10.13
Market Cap 124,472,097
Shares 17,807,167
Volume 3,679
Short Ratio
Av. Daily Volume 65,988
Stock charts supplied by TradingView

NewsSee all news

  1. Eton Pharmaceuticals and Xellia Pharmaceuticals Announce Biorphen® (phenylephrine HCl) Co-Promotion Agreement

    Xellia's US-based Hospital Sales Force Will Immediately Begin Promoting Biorphen in Collaboration with EtonAgreement Significantly Expands Biorphen Commercial Footprint and Provides Access to Institutions that Prefer

  2. Eton Pharmaceuticals Announces Commercial Availability of Biorphen® (phenylephrine HCI) Injection

    ~  Biorphen is the First and Only Ready-to-Use FDA-Approved Injectable Formulation of Phenylephrine ~ ~ Biorphen is Now Available for Order Through Major Wholesalers ~ ~ Biorphen is Eton Pharmaceuticals' First

  3. Eton Pharmaceuticals Announces Third Quarter Financial Results and Highlights Business Progress

    Biorphen® Expected to Launch by End of NovemberCompany to Host Conference Call and Webcast Today at 4:30 p.m. ET (3:30 p.m. CT) DEER PARK, Ill., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc

  4. Eton Pharmaceuticals Announces $10 Million Debt Facility with SWK Holdings

    DEER PARK, Ill., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ:ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced it has

  5. Eton Pharmaceuticals to Report Third Quarter 2019 Financial Results on Thursday, November 14, 2019

    DEER PARK, Ill., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ:ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

CRL issued July 12, 2019. NDA to be resubmitted in December 2019. Moved to 1Q 2020 due to no update.
EM-100
Allergic conjunctivitis
NDA filing planned for 2020.
ET-102
Multiple sclerosis
NDA to be filed in 2020.
DS-100
Intractable pain
Rolling NDA filing announced March 14, 2019. However, third-party has been granted five years of market exclusivity.
DS-200
Nutritional deficiencies
aNDA (not NDA) to be filed later in 2019.
DS-300
Nutritional deficiencies
FDA Approval announced October 22, 2019.
ET-202
Injectable hospital product
NDA filing due 1Q 2020.
EM-103
Hypothyroidism
NDA filing has been submitted - noted August 6, 2019.
ET-203
Injectable hospital product
NDA filing due 1H 2020.
EM-104
Neurological indication
PDUFA date March 17, 2020.
EM-105
Lennox-Gastaut syndrome, epilepsy

Latest News

  1. Eton Pharmaceuticals and Xellia Pharmaceuticals Announce Biorphen® (phenylephrine HCl) Co-Promotion Agreement

    Xellia's US-based Hospital Sales Force Will Immediately Begin Promoting Biorphen in Collaboration with EtonAgreement Significantly Expands Biorphen Commercial Footprint and Provides Access to Institutions that Prefer

  2. Eton Pharmaceuticals Announces Commercial Availability of Biorphen® (phenylephrine HCI) Injection

    ~  Biorphen is the First and Only Ready-to-Use FDA-Approved Injectable Formulation of Phenylephrine ~ ~ Biorphen is Now Available for Order Through Major Wholesalers ~ ~ Biorphen is Eton Pharmaceuticals' First

  3. Eton Pharmaceuticals Announces Third Quarter Financial Results and Highlights Business Progress

    Biorphen® Expected to Launch by End of NovemberCompany to Host Conference Call and Webcast Today at 4:30 p.m. ET (3:30 p.m. CT) DEER PARK, Ill., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc

  4. Eton Pharmaceuticals Announces $10 Million Debt Facility with SWK Holdings

    DEER PARK, Ill., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ:ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced it has

  5. Eton Pharmaceuticals to Report Third Quarter 2019 Financial Results on Thursday, November 14, 2019

    DEER PARK, Ill., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ:ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it

  6. Eton Pharmaceuticals Announces U.S. FDA Approval of Biorphen® (phenylephrine HCI) Injection

    ~  Biorphen is the First and Only Ready-to-Use FDA-Approved Injectable Formulation of Phenylephrine ~ ~ Biorphen Eliminates Need for Compounding, Reducing Risks for Unsafe Injection Practices, Medication Administration

  7. Eton Pharmaceuticals to Participate in Lake Street 3rd Annual Best Ideas Growth Conference

    DEER PARK, Ill., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ:ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that